Jinzhong Duanmu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jinzhong Duanmu has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Benqiang Rao
Beijing Shijitan Hospital Affiliated Capital Medical University
1 shared publication - Shimin Chen
Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT 06520, USA
1 shared publication - Zhiwei Hu
Pelotonia Institute for Immuno-Oncology Center for Antibody Therapeutics, The OSU James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, USA
1 shared publication
Latest Publications
- Open Access
- 26 May 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 235
Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivoin mice
The objective of this study was to develop a ligand-targeted photodynamic therapy (tPDT) by conjugating factor VII (fVII) protein with photosensitiser verteporfin in order to overcome the poor selectivity and enhance the effect of non-targeted PDT (ntPDT) for cancer. fVII is a natural ligand for receptor tissue factor (TF) with high affinity and specificity. The reason for targeting receptor TF for the development of tPDT is that TF is a common but specific target on angiogenic tumour vascular endothelial cells (VEC) and many types of tumour cells, including solid tumours and leukaemia.
- 26 May 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 235
Open AccessTargeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivoin mice
The objective of this study was to develop a ligand-targeted photodynamic therapy (tPDT) by conjugating factor VII (fVII) protein with photosensitiser verteporfin in order to overcome the poor selectivity and enhance the effect of non-targeted PDT (ntPDT) for cancer. fVII is a natural ligand for receptor tissue factor (TF) with high affinity and specificity. The reason for targeting receptor TF for the development of tPDT is that TF is a common but specific target on angiogenic tumour vascular endothelial cells (VEC) and many types of tumour cells, including solid tumours and leukaemia.